Enterin | Gut-Brain Axis | Neurodegenerative Disease

Loading...

Enterin is aiming to become the first company
in the world to develop a novel drug that repairs the dysfunctional
gut-brain axis

in patients with neurodegenerative disease.

Learn More
In preclinical models of Parkinson’s Disease, ENT-01 displaces
α-synuclein aggregates

and restores normal signaling between the gut and the brain.

Learn More
Our lead molecule, ENT-01,
is currently in Phase 2B

for patients with Parkinson's Disease.

Learn More
Our clinical data indicates that
repair of the gut-brain axis is able to significantly improve
quality of life

by influencing multiple non-motor symptoms that affect patients with Parkinson’s Disease and other neurodegenerative conditions.

Learn More
Watch an interview with one of Enterin’s founders, Dr. Michael Zasloff, discussing a new hope
against Parkinson’s,

autism and other neurodegenerative diseases.

WATCH THE VIDEO